A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 699 participants.
Also called NCT07187115
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 699 participants
- Sponsor
- Registry
-
NCT07187115
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Hong Kong SAR China, Spain
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07187115. Randomized; no masking; primary purpose treatment. Start 2025-11-07 (actual); primary completion 2027-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
- Acronym
- OPTIMIZE
- Condition
- Atrial Fibrillation (AF)
- Condition
- Persistant Atrial Fibrillation
- Intervention (Device)
- FARAPOINT Pulsed Field Ablation System
- Intervention (Device)
- OptiMap System (non-ablative)
- Intervention (Device)
- FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct07187115- Content hash
595784abf519748726a11777fdc26e03c87a245f8b0480b50cbb44672373fb7c